6-Diazo-5-oxo-l-norleucine (DON) was identified as a potential anti-cancer glutamine antagonist more than a half century ago,200 but its lack of substrate specificity provided too much off-target toxicity.201 H
Pancreatic cancer: advances and challenges. Cell 186, 1729–1754 (2023). Article CAS PubMed Google Scholar Hosein, A. N., Brekken, R. A. & Maitra, A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat. Rev. Gastroenterol. Hepatol. 17, 487–505 (2020). ...
Pancreatic cancer has been becoming the second cause of cancer death in the western world, and its disease burden has increased. Neoadjuvant therapy is one of the current research hotspots in the field of pancreatic cancer, aiming to improve the surgical rate and prognosis of pancreatic cancer. ...
Breaking the stromal barrier in pancreatic cancer: Advances and challenges 2024, Biochimica et Biophysica Acta - Reviews on Cancer Citation Excerpt : Targeted therapies, exemplified by stroma-targeting therapies discussed in this review, have emerged as promising avenues of therapeutic development and inno...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently detected at advanced stages, limiting treatment options to systemic chemotherapy with modest clinical responses. Here, we review recent advances in targeted therapy and immunotherapy for treating subtypes of PDAC with ...
Pancreatic cancer: advances and challenges. Cell. 2023;186(8):1729–54. Chen K, Wang Q, Li M, Guo H, Liu W, Wang F, Tian X, Yang Y. Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression. EBioMedicine. 2021;66:...
Pancreatic cancer, one of the most challenging malignancies to treat, is characterized by poor survival rates. The identification of novel effective therap
response rate in unselected PDAC patients is < 5% [7]. The major challenges to improving survival in PDAC can be distilled down to an immunosuppressive tumor microenvironment (TME) (Fig.1), few tumor-reactive T cells, and early metastatic dissemination, especially to the liver, which is ...
The Pancreatic Cancer Action Network (PanCAN) leads the way in accelerating critical progress for pancreatic cancer patients. PanCAN takes bold action by funding life-saving research, providing personalized patient services and creating a community of su
Given the clear importance of the TME in tumorigenesis, approaches to target specific features within the TME have garnered much attention. For example, in the past decade advances in immuno-oncology have led to ground-breaking therapeutic options for multiple cancer types. However, even immunotherap...